When people hear about dramatic weight loss results online, the conversation usually becomes “Which is better: Mounjaro or Ozempic?”
It’s not that simple, there’s more to it than just a straightforward answer.
These medications aren’t interchangeable, and the comparison goes beyond brand names. To understand which one may lead to better weight loss, it helps to look at what each drug actually does, how the clinical trials compare, and why two people can have completely different experiences on the same medication.
The data does suggest that Mounjaro may produce greater average weight loss in many patients. Still, trial results only tell part of the story. Your outcome can depend on factors like dosage, consistency, side effects, lifestyle habits, underlying health conditions, and how your body responds to treatment overall.
This article is for informational purposes only and does not constitute medical advice. Any decision about treatment should be made with a licensed healthcare provider after an individualized medical evaluation.
The Brands and What They Actually Are
Mounjaro is the FDA-approved brand name for tirzepatide, indicated for type 2 diabetes. Ozempic is the brand name for semaglutide, also indicated for type 2 diabetes.
When people ask whether one is better for weight loss, they are usually thinking of two related products: Zepbound (tirzepatide for chronic weight management) and Wegovy (semaglutide for chronic weight management). Both Zepbound and Wegovy carry FDA approval specifically for weight loss in adults who meet defined BMI criteria.
This distinction matters because prescribing the diabetes-labeled brand for weight loss is technically off-label. The clinical data on weight loss outcomes was generated under the obesity indications, not the diabetes ones. The active ingredients are identical, but the labeled use is not.
How They Work in the Body
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide 1, a hormone the gut releases after eating, which slows stomach emptying, reduces appetite, improves insulin response, and lowers blood glucose.
Tirzepatide takes that idea further. It activates two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP plays a separate role in fat metabolism and energy balance.
Activating both pathways in tandem appears to produce additive effects on appetite suppression and metabolic function, though the precise mechanisms are still being mapped. Our overview of compounded tirzepatide as a dual-action peptide walks through this in more detail.
Both medications were originally developed for type 2 diabetes management, where they showed glycemic improvements that exceeded older drug classes.
The weight loss observed in those diabetes trials was significant enough that researchers ran dedicated obesity programs (the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide), which produced the data that supported the FDA approvals of Wegovy and Zepbound for chronic weight management.
The First Direct Comparison
Before 2025, comparing tirzepatide and semaglutide meant comparing separate trials with different patient groups, different protocols, and different endpoints. Indirect comparisons can be useful, but they always carry caveats.
That changed with the SURMOUNT-5 trial published in the New England Journal of Medicine. The study randomized 751 adults with obesity or overweight (with at least one weight-related comorbidity, and without type 2 diabetes) to receive either tirzepatide at the maximum tolerated dose (10 or 15 mg) or semaglutide at the maximum tolerated dose (1.7 or 2.4 mg) for 72 weeks.
At 72 weeks, the tirzepatide group lost an average of 20.2% of body weight. The semaglutide group lost an average of 13.7%.
Tirzepatide also outperformed semaglutide on every key secondary endpoint, including the percentage of participants reaching weight reductions of at least 10%, 15%, 20%, and 25%.
That is, by any measure, a meaningful difference.
Why the Numbers Don’t Settle the Question
What an average tells you is not what your individual outcome will be. Trials measure means and medians; people live as individuals.
A few things are worth holding in mind. The 13.7% mean weight loss seen with semaglutide is itself a remarkable result clinically, well above what any non-surgical intervention produced before this drug class arrived.
For most patients with obesity, that level of weight reduction translates into significant improvements in cardiometabolic markers, sleep apnea, joint pain, and other comorbidities. Individual response also varies in ways that cannot be predicted in advance: some patients respond better to semaglutide than to tirzepatide for reasons that are not fully understood.
And tolerability matters as much as efficacy. A medication with slightly higher trial-average weight loss is not the better choice if a patient cannot tolerate it consistently enough to reach a therapeutic dose.
There is also a practical reality. The medications need to be available, affordable, and sustainable for the patient over the long term. None of those factors appear in the SURMOUNT-5 weight curve.
One additional disclosure worth noting: SURMOUNT-5 was funded by Eli Lilly, the manufacturer of tirzepatide. That is a routine conflict of interest disclosure, not a reason to discount the result. Phase 3 trials are run under strict protocols, and NEJM peer review is substantial. But it is the kind of context an honest reading of the data should include.
Side Effect Profiles
The two drugs share most of their adverse event profile, with gastrointestinal effects leading the list during dose escalation. There are some real differences in how those effects tend to present.
Patients on semaglutide more commonly report nausea and constipation. Patients on tirzepatide more commonly report diarrhea, with somewhat less nausea on average.
In SURMOUNT-5, gastrointestinal adverse events leading to treatment discontinuation occurred at 5.6% with semaglutide and 2.7% with tirzepatide. Both drugs become significantly easier to tolerate once a patient is past the dose-escalation phase and at steady state.
Both medications carry the same FDA boxed warning regarding thyroid C-cell tumors, based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use either medication.
Cost, Coverage, and Real-World Access
Branded Zepbound and Wegovy can be expensive without insurance coverage, and coverage for weight management is inconsistent across plans.
Some patients access these medications through compounding pharmacies, though the regulatory and supply environment has shifted considerably since the FDA removed both from the official drug shortage list. Compounded options remain legal in specific clinical circumstances, but the rules are now narrower.
For patients exploring their options, our prescribing and safety information pageexplains how Precision Telemed approaches sourcing, dosing, and monitoring across both medications.
Another option some providers now use is a microdosed dual GIP/GLP-1 protocol, which aims to reduce side effect burden and cost while maintaining clinical effect. These are off-label approaches and should only be initiated under provider supervision.
So Which One Is Right for You?
If the question is which medication produced more weight loss in the only direct head-to-head trial published so far, the answer is tirzepatide. If the question is which medication is right for an individual person, the data alone does not answer that. It points to a reasonable starting place, but the right protocol depends on health history, prior response to other medications, side effect tolerance, cost reality, comorbidities, and lifestyle.
A provider who reviews your full clinical picture is the only person who can give you a meaningful recommendation. That is not a deflection. It is just accurate.
Talk to a Provider Who Knows Both Medications
If you are weighing these options, the most useful next step is a conversation with a clinician who prescribes both and can speak to how the choice plays out in real practice.
A 15-minute consultation with the Precision Telemed team can put the trial data in the context of your own health, lab work, and goals, with no cost or obligation. Book your initial visit!
This article is for informational purposes only and does not constitute medical advice. Individual results vary. Consult a licensed healthcare provider before starting, stopping, or changing any prescription medication.